Type of Cancer: Phase 1-2 trial evaluating anti-TGF agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (RRMM).
Sponsor: Sanofi
Phase / Design:
Population:
Please let us know you!
